Corion Biotech signed an agreement with “Officina Farmaceutica” University of Turin Cell factory (Italy) for GMP production of CB-ChMF-11 biological against preeclampsia. Corion Biotech signed an agreement with “Officina Farmaceutica” University of Turin Cell factory (Italy) for GMP production of CB-ChMF-11 biological against preeclampsia.amministratorecorion2021-09-07T11:59:15+02:0001/07/2021|Read More
Corion Biotech S.r.l. receives European Medicines Agency (EMA) Orphan Drug Designation for Preeclampsia. Corion Biotech S.r.l. receives European Medicines Agency (EMA) Orphan Drug Designation for Preeclampsia.amministratorecorion2021-09-07T11:56:10+02:0012/05/2021|Read More
LIFTT and FINDE 1Mln round investment LIFTT and FINDE 1Mln round investmentamministratorecorion2021-09-07T12:01:36+02:0031/07/2020|Read More
Corion Biotech Granted Patent in Europe for the treatment of Epithelial Tumors by a Placental Mesenchymal Cells-derived biological. Corion Biotech Granted Patent in Europe for the treatment of Epithelial Tumors by a Placental Mesenchymal Cells-derived biological.amministratorecorion2021-09-07T11:29:08+02:0020/01/2018|Read More
Corion Biotech Granted Patent in Europe for the Treatment of Preeclampsia with a Placenta-derived biological. Corion Biotech Granted Patent in Europe for the Treatment of Preeclampsia with a Placenta-derived biological.amministratorecorion2023-11-16T11:42:37+01:0012/03/2016|Read More